Chimeric Antigen Receptor Therapy

By C. June, Michel Sadelain. New England Journal of Medicine, 2018

1,841 citations recorded by the source corpus.

Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors. Toxic e...

Subfields: Oncology, Physiology

View Paper: https://www.semanticscholar.org/paper/31c5b47fadc00b29ecb2eeb1851d2486191399ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno
3. I. Melero
4. Weiqi Hong

In Physiology

1. J. Kochenderfer

Citations in the corpus

• Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects (2020, background): “One promising area in immunotherapy is the application of genetically engineered T cells, known as chimeric antigen receptor (CAR) T cells, which allow the targeting of tumorassociated antigens and could enhance the therapy response.(218,219) The preparation of functional CAR T cells requires severa”
• Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma (2021, background): “Compared to other MSLN-targeted therapies, CAR T cell therapy offers the potential to promote immune surveillance and avoid tumor recurrence through CAR T cell persistence in the patients’ body and then reactivation after a further antigen encounter [132].”
• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “Malignancy-associated antigens of solid tumors may in some cases be more widely expressed on normal tissues, which may increase the likelihood of CAR-mediated damage to essential normal cells [6,89,90].”
• Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”